Condition
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials and research
Research outlook What's coming for Pancreatic cancer: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 2 Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials that are recruiting, at sites in 3 countries (most in Denmark (1), Japan (1), Greece (1)). By phase: Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 3Countries
All recruiting trials (2)
-
NalIriFOx as first-line therapy for metastatic pancreatic cancer
This real-world study will see how NalIriFOx performs as a first-line treatment for metastatic pancreatic cancer in several Greek centers.
-
First-in-human imaging study of 68Ga-DFC413 and comparison with 68Ga-NNS309 in solid tumors
This study tests a new radioactive imaging agent, 68Ga-DFC413, to see how it behaves in patients with several solid tumors and compares it to 68Ga-NNS309.
Related topics
Quick answers
How many Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in Denmark (1 trial), Japan (1 trial), Greece (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.